Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients.

Hemodialysis international. International Symposium on Home Hemodialysis

Sunder-Plassmann G, Hörl WH.
PMID: 28452434
Hemodial Int. 2001 Jan;5(1):86-91. doi: 10.1111/hdi.2001.5.1.86.

The pathophysiology of hyperhomocysteinemia in end-stage renal disease (ESRD) patients includes impaired remethylation of homocysteine (Hcy) to methionine, inhibition of extrarenal Hcy metabolism by uremic solutes, a block in decarboxylation of cysteinesulfinic acid, impaired [adenosylmethionine]/[adenosylhomocysteine] ratio, and a probable...

Cite
Sunder-Plassmann G, Hörl WH. Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients. Hemodial Int. 2001;5(1):86-91doi: 10.1111/hdi.2001.5.1.86.
Sunder-Plassmann, G., & Hörl, W. H. (2001). Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients. Hemodialysis international. International Symposium on Home Hemodialysis, 5(1), 86-91. https://doi.org/10.1111/hdi.2001.5.1.86
Sunder-Plassmann, G, and Hörl, Walter H. "Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients." Hemodialysis international. International Symposium on Home Hemodialysis vol. 5,1 (2001): 86-91. doi: https://doi.org/10.1111/hdi.2001.5.1.86
Sunder-Plassmann G, Hörl WH. Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients. Hemodial Int. 2001 Jan;5(1):86-91. doi: 10.1111/hdi.2001.5.1.86. PMID: 28452434.
Copy Download .nbib Format: NLM
Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey.

Nephron extra

Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassmann G, Kotanko P.
PMID: 22740033
Nephron Extra. 2012 Jan;2(1):147-58. doi: 10.1159/000339102. Epub 2012 Jun 01.

BACKGROUND/AIMS: Uromodulin-associated kidney disease (UAKD) is caused by uromodulin mutations and leads to end-stage renal disease. Our objective was to examine the epidemiology of UAKD.METHODS: Data from all UAKD families in Austria were collected. Patients included in the Austrian...

Cite
Lhotta K, Piret SE, Kramar R, et al. Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey. Nephron Extra. 2012;2(1):147-58doi: 10.1159/000339102.
Lhotta, K., Piret, S. E., Kramar, R., Thakker, R. V., Sunder-Plassmann, G., & Kotanko, P. (2012). Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey. Nephron extra, 2(1), 147-58. https://doi.org/10.1159/000339102
Lhotta, Karl, et al. "Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey." Nephron extra vol. 2,1 (2012): 147-58. doi: https://doi.org/10.1159/000339102
Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassmann G, Kotanko P. Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey. Nephron Extra. 2012 Jan;2(1):147-58. doi: 10.1159/000339102. Epub 2012 Jun 01. PMID: 22740033; PMCID: PMC3383240.
Copy Download .nbib Format: NLM
CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Clinical pharmacology and therapeutics

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ.
PMID: 30239993
Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725.

No abstract available.

Cite
van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017;102(1):152doi: 10.1002/cpt.725.
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Dávila-Fajardo, C. L., Deneer, V. H., Dolžan, V., Ingelman-Sundberg, M., Jönsson, S., Karlsson, M. O., Kriek, M., Mitropoulou, C., Patrinos, G. P., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J., Sunder-Plassmann, G., Toffoli, G., Turner, R. M., van Rhenen, M. H., Swen, J. J., Guchelaar, H. J. (2017). CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clinical pharmacology and therapeutics, 102(1), 152. https://doi.org/10.1002/cpt.725
van der Wouden, C H, et al. "CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium." Clinical pharmacology and therapeutics vol. 102,1 (2017): 152. doi: https://doi.org/10.1002/cpt.725
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ. CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. PMID: 30239993.
Copy Download .nbib Format: NLM
Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas.

Health science reports

Geusau A, Borik-Heil L, Skalicky S, Mildner M, Grillari J, Hackl M, Sunder-Plassmann R.
PMID: 33251338
Health Sci Rep. 2020 Nov 19;3(4):e205. doi: 10.1002/hsr2.205. eCollection 2020 Dec.

Micro RNAs (miRNAs) are considered as promising biomarkers for skin cancer. By next generation sequencing (NGS), we measured and compared miRNA expression profiles of tumor, peri-lesional, and control tissue of immunosuppressed organ transplant recipients (OTR), suffering from localized cutaneous...

Cite
Geusau A, Borik-Heil L, Skalicky S, et al. Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas. Health Sci Rep. 2020;3(4):e205doi: 10.1002/hsr2.205.
Geusau, A., Borik-Heil, L., Skalicky, S., Mildner, M., Grillari, J., Hackl, M., & Sunder-Plassmann, R. (2020). Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas. Health science reports, 3(4), e205. https://doi.org/10.1002/hsr2.205
Geusau, Alexandra, et al. "Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas." Health science reports vol. 3,4 (2020): e205. doi: https://doi.org/10.1002/hsr2.205
Geusau A, Borik-Heil L, Skalicky S, Mildner M, Grillari J, Hackl M, Sunder-Plassmann R. Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas. Health Sci Rep. 2020 Nov 19;3(4):e205. doi: 10.1002/hsr2.205. eCollection 2020 Dec. PMID: 33251338; PMCID: PMC7676459.
Copy Download .nbib Format: NLM
Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis.

Frontiers in medicine

Gaggl M, Repitz A, Riesenhuber S, Aigner C, Sliber C, Fraunschiel M, Cejka D, Sunder-Plassmann G.
PMID: 34552945
Front Med (Lausanne). 2021 Sep 06;8:711034. doi: 10.3389/fmed.2021.711034. eCollection 2021.

No abstract available.

Cite
Gaggl M, Repitz A, Riesenhuber S, et al. Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis. Front Med (Lausanne). 2021;8:711034doi: 10.3389/fmed.2021.711034.
Gaggl, M., Repitz, A., Riesenhuber, S., Aigner, C., Sliber, C., Fraunschiel, M., Cejka, D., & Sunder-Plassmann, G. (2021). Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis. Frontiers in medicine, 8711034. https://doi.org/10.3389/fmed.2021.711034
Gaggl, Martina, et al. "Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis." Frontiers in medicine vol. 8 (2021): 711034. doi: https://doi.org/10.3389/fmed.2021.711034
Gaggl M, Repitz A, Riesenhuber S, Aigner C, Sliber C, Fraunschiel M, Cejka D, Sunder-Plassmann G. Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis. Front Med (Lausanne). 2021 Sep 06;8:711034. doi: 10.3389/fmed.2021.711034. eCollection 2021. PMID: 34552945; PMCID: PMC8450526.
Copy Download .nbib Format: NLM
[Hypertension and surgery].

Medizinische Klinik

SUNDER-PLASSMANN P.
PMID: 13835726
Med Klin. 1960 Apr 15;55:627-9.

No abstract available.

Cite
SUNDER-PLASSMANN P. [Hypertension and surgery]. Med Klin. 1960;55:627-9
SUNDER-PLASSMANN, P. (1960). [Hypertension and surgery]. Medizinische Klinik, 55627-9.
SUNDER-PLASSMANN, P. "[Hypertension and surgery]." Medizinische Klinik vol. 55 (1960): 627-9.
SUNDER-PLASSMANN P. [Hypertension and surgery]. Med Klin. 1960 Apr 15;55:627-9. German. PMID: 13835726.
Copy Download .nbib Format: NLM
Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots.

Journal of clinical medicine

Auer-Grumbach M, Rettl R, Ablasser K, Agis H, Beetz C, Duca F, Gattermeier M, Glaser F, Hacker M, Kain R, Kaufmann B, Kovacs GG, Lampl C, Ljevakovic N, Nagele J, Pölzl G, Quasthoff S, Raimann B, Rauschka H, Reiter C, Skrahina V, Schuhfried O, Sunder-Plassmann R, Verheyen ND, Wanschitz J, Weber T, Windhager R, Wurm R, Zimprich F, Löscher WN, Bonderman D.
PMID: 32674397
J Clin Med. 2020 Jul 14;9(7). doi: 10.3390/jcm9072234.

BACKGROUND: Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominantly inherited disorder caused by an accumulation of amyloid fibrils in tissues due to mutations in the transthyretin (METHODS: Within the period of 2014-2019, patients with ATTR-associated cardiomyopathy and/or unexplained progressive...

Cite
Auer-Grumbach M, Rettl R, Ablasser K, et al. Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. J Clin Med. 2020;9(7)doi: 10.3390/jcm9072234.
Auer-Grumbach, M., Rettl, R., Ablasser, K., Agis, H., Beetz, C., Duca, F., Gattermeier, M., Glaser, F., Hacker, M., Kain, R., Kaufmann, B., Kovacs, G. G., Lampl, C., Ljevakovic, N., Nagele, J., Pölzl, G., Quasthoff, S., Raimann, B., Rauschka, H., Reiter, C., Skrahina, V., Schuhfried, O., Sunder-Plassmann, R., Verheyen, N. D., Wanschitz, J., Weber, T., Windhager, R., Wurm, R., Zimprich, F., Löscher, W. N., & Bonderman, D. (2020). Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of clinical medicine, 9(7), . https://doi.org/10.3390/jcm9072234
Auer-Grumbach, Michaela, et al. "Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots." Journal of clinical medicine vol. 9,7 (2020). doi: https://doi.org/10.3390/jcm9072234
Auer-Grumbach M, Rettl R, Ablasser K, Agis H, Beetz C, Duca F, Gattermeier M, Glaser F, Hacker M, Kain R, Kaufmann B, Kovacs GG, Lampl C, Ljevakovic N, Nagele J, Pölzl G, Quasthoff S, Raimann B, Rauschka H, Reiter C, Skrahina V, Schuhfried O, Sunder-Plassmann R, Verheyen ND, Wanschitz J, Weber T, Windhager R, Wurm R, Zimprich F, Löscher WN, Bonderman D. Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. J Clin Med. 2020 Jul 14;9(7). doi: 10.3390/jcm9072234. PMID: 32674397; PMCID: PMC7408866.
Copy Download .nbib Format: NLM
A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report.

Case reports in transplantation

Gaggl M, Kain R, Jaksch P, Haider D, Mundigler G, Voigtländer T, Sunder-Plassmann R, Rommer P, Klepetko W, Sunder-Plassmann G.
PMID: 23691425
Case Rep Transplant. 2013;2013:905743. doi: 10.1155/2013/905743. Epub 2013 Apr 07.

Introduction. Fabry disease is a rare X-linked lysosomal storage disorder, characterized by an α-galactosidase A deficiency resulting in globotriaosylceramide storage within cells. Subsequently, various organ systems are involved, clinically the most important are kidneys, the heart, and the peripheral...

Cite
Gaggl M, Kain R, Jaksch P, et al. A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report. Case Rep Transplant. 2013;2013:905743doi: 10.1155/2013/905743.
Gaggl, M., Kain, R., Jaksch, P., Haider, D., Mundigler, G., Voigtländer, T., Sunder-Plassmann, R., Rommer, P., Klepetko, W., & Sunder-Plassmann, G. (2013). A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report. Case reports in transplantation, 2013905743. https://doi.org/10.1155/2013/905743
Gaggl, Martina, et al. "A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report." Case reports in transplantation vol. 2013 (2013): 905743. doi: https://doi.org/10.1155/2013/905743
Gaggl M, Kain R, Jaksch P, Haider D, Mundigler G, Voigtländer T, Sunder-Plassmann R, Rommer P, Klepetko W, Sunder-Plassmann G. A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report. Case Rep Transplant. 2013;2013:905743. doi: 10.1155/2013/905743. Epub 2013 Apr 07. PMID: 23691425; PMCID: PMC3638525.
Copy Download .nbib Format: NLM
Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report.

Case reports in obstetrics and gynecology

Haninger-Vacariu N, El-Hadi S, Pauler U, Foretnik M, Kain R, Prohászka Z, Schmidt A, Skuban N, Barth JA, Sunder-Plassmann G.
PMID: 31934472
Case Rep Obstet Gynecol. 2019 Dec 21;2019:1030259. doi: 10.1155/2019/1030259. eCollection 2019.

Our patient was a 37-year-old woman with Fabry disease (

Cite
Haninger-Vacariu N, El-Hadi S, Pauler U, et al. Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. Case Rep Obstet Gynecol. 2019;2019:1030259doi: 10.1155/2019/1030259.
Haninger-Vacariu, N., El-Hadi, S., Pauler, U., Foretnik, M., Kain, R., Prohászka, Z., Schmidt, A., Skuban, N., Barth, J. A., & Sunder-Plassmann, G. (2019). Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. Case reports in obstetrics and gynecology, 20191030259. https://doi.org/10.1155/2019/1030259
Haninger-Vacariu, Natalja, et al. "Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report." Case reports in obstetrics and gynecology vol. 2019 (2019): 1030259. doi: https://doi.org/10.1155/2019/1030259
Haninger-Vacariu N, El-Hadi S, Pauler U, Foretnik M, Kain R, Prohászka Z, Schmidt A, Skuban N, Barth JA, Sunder-Plassmann G. Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. Case Rep Obstet Gynecol. 2019 Dec 21;2019:1030259. doi: 10.1155/2019/1030259. eCollection 2019. PMID: 31934472; PMCID: PMC6942789.
Copy Download .nbib Format: NLM
100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021.

Journal of inherited metabolic disease

Ramoser G, Caferri F, Radlinger B, Brunner-Krainz M, Herbst S, Huemer M, Hufgard-Leitner M, Kircher SG, Konstantopoulou V, Löscher W, Möslinger D, Plecko B, Spenger J, Stulnig T, Sunder-Plassmann G, Wortmann S, Scholl-Bürgi S, Karall D.
PMID: 34595757
J Inherit Metab Dis. 2021 Sep 30; doi: 10.1002/jimd.12442. Epub 2021 Sep 30.

Inherited metabolic disorders (IMDs) are a heterogeneous group of rare disorders characterized by disruption of metabolic pathways. To date, data on incidence and prevalence of IMDs are limited. Taking advantage of a functioning network within the Austrian metabolic group,...

Cite
Ramoser G, Caferri F, Radlinger B, et al. 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. J Inherit Metab Dis. 2021;doi: 10.1002/jimd.12442.
Ramoser, G., Caferri, F., Radlinger, B., Brunner-Krainz, M., Herbst, S., Huemer, M., Hufgard-Leitner, M., Kircher, S. G., Konstantopoulou, V., Löscher, W., Möslinger, D., Plecko, B., Spenger, J., Stulnig, T., Sunder-Plassmann, G., Wortmann, S., Scholl-Bürgi, S., Karall, D. (2021). 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. Journal of inherited metabolic disease, . https://doi.org/10.1002/jimd.12442
Ramoser, Gabriele, et al. "100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021." Journal of inherited metabolic disease vol. (2021). doi: https://doi.org/10.1002/jimd.12442
Ramoser G, Caferri F, Radlinger B, Brunner-Krainz M, Herbst S, Huemer M, Hufgard-Leitner M, Kircher SG, Konstantopoulou V, Löscher W, Möslinger D, Plecko B, Spenger J, Stulnig T, Sunder-Plassmann G, Wortmann S, Scholl-Bürgi S, Karall D. 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. J Inherit Metab Dis. 2021 Sep 30; doi: 10.1002/jimd.12442. Epub 2021 Sep 30. PMID: 34595757.
Copy Download .nbib Format: NLM
Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.

Clinical journal of the American Society of Nephrology : CJASN

Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, Gleiss A, Hörl WH, Sunder-Plassmann G.
PMID: 34470831
Clin J Am Soc Nephrol. 2021 Oct;16(10):1512-1521. doi: 10.2215/CJN.03850321. Epub 2021 Sep 01.

BACKGROUND AND OBJECTIVES: Whether iron supplementation in patients on hemodialysis could be delivered by less frequent but higher single doses compared with the currently more common higher-frequency schedules of lower single iron doses is unknown.DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:...

Cite
Bielesz B, Lorenz M, Monteforte R, et al. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021;16(10):1512-1521doi: 10.2215/CJN.03850321.
Bielesz, B., Lorenz, M., Monteforte, R., Prikoszovich, T., Gabriel, M., Wolzt, M., Gleiss, A., Hörl, W. H., & Sunder-Plassmann, G. (2021). Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clinical journal of the American Society of Nephrology : CJASN, 16(10), 1512-1521. https://doi.org/10.2215/CJN.03850321
Bielesz, Bernhard, et al. "Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial." Clinical journal of the American Society of Nephrology : CJASN vol. 16,10 (2021): 1512-1521. doi: https://doi.org/10.2215/CJN.03850321
Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, Gleiss A, Hörl WH, Sunder-Plassmann G. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021 Oct;16(10):1512-1521. doi: 10.2215/CJN.03850321. Epub 2021 Sep 01. PMID: 34470831; PMCID: PMC8499011.
Copy Download .nbib Format: NLM
FHR-5 Serum Levels and .

Frontiers in immunology

Garam N, Cserhalmi M, Prohászka Z, Szilágyi Á, Veszeli N, Szabó E, Uzonyi B, Iliás A, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Stajic N, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Józsi M, Csuka D.
PMID: 34566977
Front Immunol. 2021 Sep 10;12:720183. doi: 10.3389/fimmu.2021.720183. eCollection 2021.

BACKGROUND: Factor H-related protein 5 (FHR-5) is a member of the complement Factor H protein family. Due to the homology to Factor H, the main complement regulator of the alternative pathway, it may also be implicated in the pathomechanism...

Cite
Garam N, Cserhalmi M, Prohászka Z, et al. FHR-5 Serum Levels and . Front Immunol. 2021;12:720183doi: 10.3389/fimmu.2021.720183.
Garam, N., Cserhalmi, M., Prohászka, Z., Szilágyi, �. �., Veszeli, N., Szabó, E., Uzonyi, B., Iliás, A., Aigner, C., Schmidt, A., Gaggl, M., Sunder-Plassmann, G., Bajcsi, D., Brunner, J., Dumfarth, A., Cejka, D., Flaschberger, S., Flögelova, H., Haris, �. �., Hartmann, �. �., Heilos, A., Mueller, T., Rusai, K., Arbeiter, K., Hofer, J., Jakab, D., Sinkó, M., Szigeti, E., Bereczki, C., Janko, V., Kelen, K., Reusz, G. S., Szabó, A. J., Klenk, N., Kóbor, K., Kojc, N., Knechtelsdorfer, M., Laganovic, M., Lungu, A. C., Meglic, A., Rus, R., Kersnik Levart, T., Macioniene, E., Miglinas, M., Pawłowska, A., Stompór, T., Podracka, L., Rudnicki, M., Mayer, G., Rysava, R., Reiterova, J., Saraga, M., Seeman, T., Zieg, J., Sládková, E., Stajic, N., Szabó, T., Capitanescu, A., Stancu, S., Tisljar, M., Galesic, K., Tislér, A., Vainumäe, I., Windpessl, M., Zaoral, T., Zlatanova, G., Józsi, M., & Csuka, D. (2021). FHR-5 Serum Levels and . Frontiers in immunology, 12720183. https://doi.org/10.3389/fimmu.2021.720183
Garam, Nóra, et al. "FHR-5 Serum Levels and ." Frontiers in immunology vol. 12 (2021): 720183. doi: https://doi.org/10.3389/fimmu.2021.720183
Garam N, Cserhalmi M, Prohászka Z, Szilágyi Á, Veszeli N, Szabó E, Uzonyi B, Iliás A, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Stajic N, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Józsi M, Csuka D. FHR-5 Serum Levels and . Front Immunol. 2021 Sep 10;12:720183. doi: 10.3389/fimmu.2021.720183. eCollection 2021. PMID: 34566977; PMCID: PMC8461307.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries